• Patients, Family and Friends to Take Part in Variety of Rare Disease Day Events Worldwide
  • Topline Results Announced for Phase 3 Trial Testing GS010 in LHON Patients
  • FDA Revising ‘Draft Guidance’ on Developing Treatments for Rare Diseases
  • Certain MELAS Patients Have Higher Fear of Disease Progression, Study Shows
  • Healthcare Utilization of Mitochondrial Disease Patients Much More Costly Than General Population
  • Genetic Mutations Affecting Protein Production Identified in Mitochondrial Disease
  • Mitochondrial Surveillance Mechanism Is Critical for Genomic Stability, Study Shows
  • AOX Enzyme May Alleviate Symptoms of Mitochondrial Disease, Mouse Study Shows
  • Entrada Raises $59M to Advance Program to Treat Rare, Deadly Mitochondrial Disease
  • Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish
  • GS010 Improves Visual Acuity, Quality of Life in LHON Patients, Phase 3 Trial Shows
  • NeuroVive Secures Funding to Advance NV354 for Potential Mitochondrial Disease Treatment